Abstract:e16523 Background: Non-clear cell renal carcinoma (nccRCC) usually had a poorer response to tyrosine kinase inhibitors (TKIs) due to its heterogeneity and rarity. The combination of immunotherapy with TKIs has shown promising efficacy in ccRCC. However, for nccRCC failed standard first-line TKI therapy, the second-line option is still limited. This real-world study aimed to evaluate the efficacy of immune-targeted combination therapy versus TKI monotherapy as the second-line regimen in patients with metastatic nccRCC who failed first-line TKI therapy. Methods: Demographic and clinicopathological data of patients with metastatic nccRCC who were admitted into the Sun Yat-sen University Cancer Center between October, 2011 and September, 2020 were retrospectively collected. All patients failed in first-line TKI therapy and received second-line TKI alone (TKI group) or TKI plus PD-1 therapy (combination group). Efficacy including the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) was calculated. The differences on baseline characteristics and efficacy between the two groups were compared. Results: Totally 67 patients were included, with a median age of 50 (interquartile 37-60) years. The median follow-up time was 32.7 (interquartile 21.6-53.0) months. The overall ORR, DCR was 37.3% and 56.7%, respectively. The overall second-line PFS was 7.2 (95% CI: 5.8-8.5) months and OS was 53.2 (18.4-88.0) months. Baseline characteristics between the combination group (n = 45) and the TKI group (n = 22) did not differ significantly except that the combination group had more proportion of liver metastasis (20.9% vs 4.5%, P = 0.025). The combination group had a significantly longer PFS compared with the TKI group [median PFS (95% CI): 9.2 (6.4-12.0) vs 5.2 (2.9-7.5) months, P = 0.001]. Similarly, ORR (48.9% vs 13.6, P = 0.005) and DCR (71.1% vs 27.3%, P = 0.001) was remarkably improved in the combination group. The superior efficacy over TKI monotherapy was more prominent in the younger (< 60 years), male, and patients with lower KPS, IMDC intermediate/poor-risk, non-hereditary RCC and multiple metastatic sites. Conclusions: Immune-targeted combination therapy was effective in the treatment of metastatic nccRCC who failed first-line TKIs. Subgroup analyses of PFS, ORR and DCR in patients receiving second-line treatment. Subgroup median PFS (95% CI), m P value ORR, n (%) P value DCR, n (%) P value Total 7.2 (5.8-8.5) 25 (37.3) 38 (56.7) Regimen 0.001 0.005 0.001 TKI 5.2 (2.9-7.5) 3 (13.6) 6 (27.3) Combination 9.2 (6.4-12.0) 22 (48.9) 32 (71.1) IMDC risk group 0.272 0.521 0.431 Favorable 5.4 (4.2-6.7) 1 (16.7) 3 (50.0) Intermediate 7.9 (5.4-10.4) 19 (40.4) 29 (61.7) Poor 4.6 (2.2-7.0) 5 (35.7) 6 (42.9)

Validation of the Meet-URO Score in Metastatic Clear Cell Renal Cell Carcinoma Patients Receiving Second or Third-Line Tyrosine Kinase Inhibitors-Immune Checkpoint Inhibitors Combination Therapy

Prognostic model for clear-cell renal cell carcinoma based on natural killer cell-related genes.

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

European Society of Cardiology-Acute Cardiovascular Care Association Position paper on acute heart failure: A call for interdisciplinary care

Thoughts on the Future of Great Ape Research

External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors

First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety

Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second‐line treatment with tyrosine kinase inhibitor following first‐line immune‐oncology combination therapy

ATMPKs: a gene family of plant MAP kinases in Arabidopsis thaliana

Checkpoint Molecule PD-1-assisted CD8+ T Lymphocyte Count in Tumor Microenvironment Predicts Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.

Clinical effectiveness of second-line TKI plus PD-1 following targeted therapy in patients with metastatic non-clear cell renal cell carcinoma: A real-world study.

Prognostic value of systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with systemic therapy: a meta-analysis

Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study.

Validation of the MSKCC Score Model in Advanced Renal Cell Carcinoma Patients Treated with VEGF-targeted Agents in China

Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study

Development and verification of a novel risk model related to ubiquitination linked with prognosis and therapeutic response in clear cell renal cell carcinoma

Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (Meet-URO 31).

A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs)

Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study